2 Information about treosulfan
Marketing authorisation indication
2.1 Treosulfan (Trecondi, Medac) in combination with fludarabine (generic) is indicated 'as part of conditioning treatment prior to allogeneic haematopoietic stem cell transplantation (alloHSCT) in adult patients with malignant and non-malignant diseases, and in paediatric patients older than 1 month with malignant diseases'.
2.2 This appraisal focuses on malignant diseases only.
Dosage in the marketing authorisation
2.3 The dosage schedule for treosulfan is available in the summary of product characteristics.
Price
2.4 Treosulfan:
-
£494.40 per 5‑vial pack of 1 g powder for solution for injection (BNF online accessed December 2019)
-
£2,434.25 per 5‑vial pack of 5 g powder for solution for injection (BNF online accessed December 2019).
2.5 Fludarabine:
-
£155.00 per vial of 50 mg powder for solution for injection (BNF online accessed November 2019).